Merck Completes Acquisition of EyeBio
Merck (NYSE: MRK) has completed the acquisition of Eyebiotech (EyeBio), now a wholly-owned subsidiary. This acquisition strengthens Merck's late-stage pipeline by adding Restoret™, a novel candidate for diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). Restoret™, a tetravalent, tri-specific antibody, showed positive results in a Phase 1b/2a study and will advance to a pivotal Phase 2b/3 trial in 2024. The transaction, treated as an asset acquisition, will result in Merck recording a $1.3 billion charge ($0.50 per share) in Q3 2024. Merck will update its financial outlook during its Q2 2024 earnings report on July 30.
- Strengthens Merck's late-stage pipeline with the addition of Restoret™.
- Restoret™ has shown positive results in Phase 1b/2a study for DME and NVAMD.
- Scheduled advancement of Restoret™ to Phase 2b/3 trial in 2024.
- Merck will record a $1.3 billion charge ($0.50 per share) in Q3 2024.
Merck's acquisition of EyeBio significantly strengthens its pipeline, particularly with the promising late-phase candidate, Restoret™, which targets diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). The transaction, however, comes with a notable financial implication—a charge of
From a financial perspective, this acquisition can be seen as a strategic move aimed at future revenue growth. The pipeline diversification into the ocular disease space aligns with Merck's long-term strategy of expanding its therapeutics portfolio. The expense will be felt in the short term, reducing the EPS for the upcoming quarter, but it reflects a typical strategy in the pharmaceutical industry: sacrificing short-term profitability for long-term gains.
Investors should be cautiously optimistic. While the initial hit to financials could be seen as a drawback, the potential market for DME and NVAMD treatments is substantial. If Restoret™ successfully navigates late-stage trials and secures FDA approval, revenue could significantly offset the initial costs.
The acquisition of EyeBio brings forward Restoret™, an investigational tetravalent, tri-specific antibody targeting the Wnt signaling pathway. This is a promising development in treating retinal diseases like DME and NVAMD. The positive results from early-phase trials are encouraging, particularly in a field with limited effective treatments.
The Wnt pathway is important for retinal health and a drug that can modulate this pathway could offer a novel, first-in-class treatment option. The advance to a pivotal Phase 2b/3 trial scheduled for the latter half of 2024 will be a critical milestone. If the results continue to be positive, this could revolutionize the standard of care for patients suffering from these debilitating conditions.
For patients and physicians, the potential for improved treatment options is exciting. However, it is essential to remain cautious until more robust data from larger trials are available.
From a market perspective, the acquisition of EyeBio by Merck is a calculated move to enter the lucrative retinal disease market. Diabetic macular edema and neovascular age-related macular degeneration affect millions globally, with significant unmet need driving demand for innovative treatments.
The timing of this acquisition is noteworthy, as the market for ophthalmic drugs is expected to grow substantially, driven by aging populations and increasing prevalence of diabetes. By securing a late-phase candidate with Restoret™, Merck positions itself to capitalize on this growing market.
However, it's important to note the competitive landscape. Major players like Regeneron and Novartis already have established treatments, so Restoret™ will need to demonstrate superior efficacy or a differentiated safety profile to capture significant market share.
Overall, this acquisition is a strategic bet that, if successful, could lead to substantial market penetration and revenue growth for Merck.
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates
“The EyeBio acquisition further diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “We are excited to welcome the EyeBio team and look forward to working together to advance Restoret for the patients that need it.”
EyeBio’s lead candidate, Restoret™ (EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site (Wnt) signaling pathway. Based on positive results from the open-label Phase 1b/2a AMARONE study in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD), Restoret is scheduled to advance into a pivotal Phase 2b/3 trial to evaluate its potential for the treatment of patients with DME in the second half of 2024.
Additional pipeline candidates include clinical and preclinical assets being developed for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal diseases.
Transaction details
Under the terms of the agreement, Merck, through a subsidiary, has acquired all outstanding shares of EyeBio. As previously disclosed, this transaction is being accounted for as an asset acquisition. Merck will record a charge of approximately
About Restoret
Restoret is an investigational, potentially first-in-class tetravalent, tri-specific Wnt antibody designed to address unmet medical need in patients with retinal diseases, including diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). Restoret is administered as an intravitreal injection seeking to eliminate vascular leakage in retinal diseases by agonizing the Wnt pathway with the goal of restoring and maintaining the blood-retinal barrier. Preclinical evidence indicates that agonizing the Wnt pathway in the retina may reduce vascular leakage.
About Merck
At Merck, known as MSD outside of
Forward-Looking Statement of Merck & Co., Inc.,
This news release of Merck & Co., Inc.,
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240712972802/en/
Media Contacts:
Robert Josephson
(203) 914-2372
Justine Moore
(347) 281-3754
Investor Contacts:
Peter Dannenbaum
(732) 594-1579
Damini Chokshi
(732) 594-1577
Source: Merck & Co., Inc.
FAQ
What is the significance of Merck's acquisition of EyeBio?
What are the financial implications of Merck's acquisition of EyeBio?
When will Restoret™ advance to the next phase of clinical trials?
How did Restoret™ perform in initial studies?
How will the acquisition of EyeBio impact Merck’s financial outlook?
